Ignite Creation Date:
2024-05-06 @ 1:40 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04085471
Status:
UNKNOWN
Last Update Posted:
2019-09-18
First Post:
2019-09-09
Brief Title:
CTHRC1 Abiomarker in Rheumatoid Arthritis Diagnosis
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
CTHRC1 Apromising Biomarker in Rheumatoid Arthritis Diagnosis
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing CTHRC1 protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis RA and furthermore its correlation with disease activity
Detailed Description:
Rheumatoid arthritis RA is a chronic progressive autoimmune disease of synovial joints Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability Currently diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints levels of acute-phase reactants such as C-reactive protein CRP erythrocyte sedimentation rateESR high titers of rheumatoid factor RF and high titers of antibodies against cyclic citrullinated peptide anti-CCP in the plasma Of interest CTHRC1 is a secreted modulator of Wnt signaling which is a key regulator of joint remodeling and promotes cell proliferation and migration Therefore CTHRC1 may contribute to multiple aspects of the pathogenic FLS behavior in RA and modulate processes that promote synovial hyperplasia and invasionThe expression pattern of CTHRC1 in pannus its role in the function of FLS relevant to cartilage damage in RA and CTHRC1s association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None